EliseApril StrChongMD

PubMed

• Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
  Guido Ghilardi, Luca Paruzzo, Vrutti Patel, Jakub Svoboda, Emeline R Chong, Eugenio Fardella, Elise A Chong, Giulia Gabrielli, Sunita D Nasta, Daniel J Landsburg, Jord...> ;Journal of Hematology & Oncology. 2024 Apr 22
• Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
  Elise A Chong, Emeline R Chong, Dylan Therwhangher, Sunita D Nasta, Daniel J Landsburg, Stefan K Barta, Jakub Svoboda, James N Gerson, Guido Ghilardi, Luca Paruzzo, Jo...> ;Transplantation and Cellular Therapy. 2024 Mar 16
• Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.
  Wisdom Akingbemi, Goldie Kurtz, Nikhil Yegya-Raman, John P Plastaras, Stephen J Schuster, Elise A Chong> ;Leukemia & Lymphoma. 2024 Mar 7
• Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
  Elise A Chong, Kingsley Gideon Kumashie, Emeline R Chong, Joseph Fabrizio, Aditi Gupta, Jakub Svoboda, Stefan K Barta, Kristy M Walsh, Ellen B Napier, Rachel K Lundber...> ;The Journal of Infectious Diseases. 2024 Mar 4
• 4 citations
  T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
  Guido Ghilardi, Joseph A Fraietta, James N Gerson, Vivianna M Van Deerlin, Jennifer J D Morrissette, Gabriel C Caponetti, Luca Paruzzo, Jaryse C Harris, Elise A Chong,...> ;Nature Medicine. 2024 Apr 1
• TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era.
  Daniel J Landsburg, Jennifer Jd Morrissette, Sunita D Nasta, Stefan K Barta, Stephen J Schuster, Jakub Svoboda, Elise A Chong, Adam Bagg> ;Blood Advances. 2023 Dec 12
• Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.
  Jackson T Bowers, Jacob Anna, Steven M Bair, Kaitlin Annunzio, Narendranath Epperla, Jerrin Joy Pullukkara, Sameh Gaballa, Michael A Spinner, Shuning Li, Marcus R Mess...> ;Blood Advances. 2023 Nov 14
• 1 citations
  Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or...
  Daniel J Landsburg, Sunita D Nasta, Jakub Svoboda, James N Gerson, Stephen J Schuster, Stefan K Barta, Elise A Chong, Heather Difilippo, Elizabeth Weber, Kathleen Cunn...> ;Transplantation and Cellular Therapy. 2023 Aug 1
• 1 citations
  Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.
  Nikhil Yegya-Raman, Christopher M Wright, Michael J LaRiviere, Jonathan A Baron, Daniel Y Lee, Daniel J Landsburg, Jakub Svoboda, Sunita D Nasta, James N Gerson, Stefa...> ;Clinical and Translational Radiation Oncology. 2023 Mar 1
• Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas.
  Daniel J Landsburg, Jennifer J D Morrissette, Stephen J Schuster, Sunita D Nasta, James N Gerson, Stefan K Barta, Jakub Svoboda, Elise A Chong, Megan S Lim> ;Oncotarget. 2022 Nov 17
• 13 citations
  Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
  Lee, Y., Guruprasad, P., Ghilardi, G., Pajarillo, R., Sauter, C., Patel, R., Ballard, H., Hong, S., Chun, I., Yang, N., Amelsberg, K., Cummins, K., Svoboda, J., Gill, ...> ;Cancer Discovery. 2022 Oct 5
• 1 citations
  Radiation Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: What Is the Right Regimen for Palliation?
  Christopher M Wright, Alexandra D Dreyfuss, Jonathan A Baron, Russell Maxwell, Amberly Mendes, Andrew R Barsky, Abigail Doucette, Jakub Svoboda, Elise A Chong, Joshua ...> ;Advances in Radiation Oncology. 2022 Jul 3
• 5 citations
  Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting.
  Sunita D Nasta, Mitchell E Hughes, Esin C Namoglu, Alfred Garfall, Heather DiFilippo, Hatcher J Ballard, Stefan K Barta, Elise A Chong, Noelle V Frey, James N Gerson, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Aug 1
• 68 citations
  Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
  Elise A. Chong, Cécile Alanio, Jakub Svoboda, Sunita D. Nasta, Daniel J. Landsburg, Simon F. Lacey, Marco Ruella, Siddharth Bhattacharyya, E. John Wherry, Stephen J. S...> ;Blood. 2021 Sep 9
• 1 citations
  Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy.
  Daniel J. Landsburg, Sunita D. Nasta, James N. Gerson, Jakub Svoboda, Elise A. Chong, Stephen J. Schuster, Stefan K. Barta, Kyle W. Robinson, Mitchell E. Hughes> ;Leukemia & Lymphoma. 2021 Aug 26
• 46 citations
  COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
  Lindsey E. Roeker, Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff, Matthew S. Davids, PK Baker, Lori A. Leslie, Kerry A. Rogers, John N. Allan, Ra...> ;Blood. 2021 Jul 23
• 5 citations
  18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma
  Andrew Ruff, Hatcher J. Ballard, Austin R. Pantel, Esin C. Namoglu, Mitchell E. Hughes, Sunita D. Nasta, Elise A. Chong, Adam Bagg, Marco Ruella, Michael D. Farwell, J...> ;Molecular Imaging and Biology. 2021 Jul 6
• 6 citations
  Palliative Radiotherapy for Diffuse Large B-cell Lymphoma.
  Christopher M. Wright, Antony I. Koroulakis, Jonathan Baron, Elise A. Chong, Yolanda D. Tseng, G. Kurtz, Michael J. LaRiviere, Sriram Venigalla, Joshua Jones, Amit Mai...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Oct 1
• 95 citations
  Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.
  Elise A. Chong, Marco Ruella, Stephen J. Schuster> ;The New England Journal of Medicine. 2021 Feb 17
• 4 citations
  Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas.
  Jonathan Baron, Christopher M. Wright, Daniel Y. Lee, Maribel Carpenter, César A. Briceño, Elise A. Chong, Amit Maity, John P. Plastaras, Ima Paydar> ;Frontiers in Oncology. 2021 Jan 1
• 3 citations
  Immunotherapy with cells.
  Elise A Chong, David L Porter> ;Hematology. American Society of Hematology. Education Program. 2020 Dec 4
• 14 citations
  CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before.
  Guido Ghilardi, Peter Braendstrup, Elise A. Chong, Stephen J. Schuster, Jakub Svoboda, Marco Ruella> ;British Journal of Haematology. 2021 May 1
• 219 citations
  Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Blood. 2020 Sep 3
• 34 citations
  BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
  Elise A. Chong, Lindsey E. Roeker, Mazyar Shadman, Matthew S. Davids, Stephen J. Schuster, Anthony R. Mato> ;Clinical Cancer Research. 2020 Jul 15
• 53 citations
  Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma
  Christopher M. Wright, Michael J. LaRiviere, Jonathan Baron, C.Z. Uche, Ying Xiao, W. Tristram Arscott, Emily J. Anstadt, Andrew R. Barsky, David Miller, Meredith I. L...> ;International Journal of Radiation Oncology, Biology, Physics. 2020 Sep 1
• Join now to see all

Abstracts/Posters

• Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
  Elise A. Chong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
  Elise A. Chong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
  Elise A. Chong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
  Elise A. Chong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
  Elise A. Chong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
  Elise A. Chong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
  Elise A. Chong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018